 |
 |
  |
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie COFUND grant agreement No 665735.
Bio4Med: International PhD Program
in Biological Bases of Human Diseases
COLLABORATIVE PhD PROJECTS BETWEEN
THE NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, WARSAW, POLAND
AND INTERNATIONAL PARTNERS
- 22 PhD projects
- Visit(s) to foreign partner laboratory
- Multidisciplinary training
- Fellowship (net) 1700 Euro/month
- Start date October 2015
The major aim of Bio4Med (Biology for Medicine) programme was to provide unique, international, inter-disciplinary and intersectoral doctoral training for Early Stage Researchers (ESRs) in the domain of biological bases of human diseases. To achieve this goal it combined 22 leading research groups at the Nencki Institute and their scientific partners from world-class laboratories located in EU Member States, Switzerland, Ukraine, Japan, Canada and US.
Research programme included basic science PhD-projects focused on molecular basis of neurodegeneration, neurological disorders, cancer and metabolic diseases. All supervising researchers engaged in the Bio4Med were at the international forefront of biomedical research and had experience in PhD student supervision. Our programme fostered young researchers’ career development and employability by addressing the following objectives:
- to offer excellent training in modern biology and endow ESRs with unique scientific knowledge, and experience in cutting-edge experimental techniques;
- to enhance research-oriented and transferable skills of ESRs;
- to promote scientific mobility via international, inter-disciplinary and inter-sectoral collaboration.
The objectives of Bio4Med were delivered through activities encompassing practical laboratory training, hands-on workshops, lectures corresponding to the theoretical aspects of doctoral projects, research-oriented generic skills courses, transferrable skills courses, progress talks and meetings. The training programme itself, focused on medically important issues, made ESRs highly attractive to commercial enterprises, particularly in biotechnology and pharmaceutical sectors.